The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.

Abstract:

INTRODUCTION:Depression and psychosis are two of the most severe neuropsychiatric symptoms (NPS) in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Both NPS have negative effects on cognitive performance and life expectancy. The current study aimed to investigate and compare monoaminergic etiologies between both neurodegenerative conditions, given the lack of an efficient pharmacological treatment until present. METHODS:Eleven behaviorally relevant brain regions of the left frozen hemisphere of 10 neuropathologically confirmed AD patients with/without depression (AD + D/-D; 5 were psychotic within AD + D), 10 confirmed DLB patients, all of whom were depressed (DLB + D; 5 psychotic patients), and, finally, 10 confirmed control subjects were regionally dissected. All patients were retrospectively assessed before death using the Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD) and Cornell Scale for Depression in Dementia amongst others. The concentrations of dopamine (DA), serotonin (5-HT), (nor)adrenaline and respective metabolites, i.e. 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), 5-hydroxy-3-indoleacetic acid (5-HIAA), and, 3-methoxy-4-hydroxyphenylglycol (MHPG), were determined using reversed-phase high-performance liquid chromatography with electrochemical detection. RESULTS:DLB subjects had the overall lowest monoamine and metabolite concentrations regarding 33 out of 41 significant monoaminergic group alterations. Moreover, MHPG levels were significantly decreased in almost 8 out of 11 brain regions of DLB- compared to AD patients. We also observed the lowest 5-HT and 5-HIAA levels, and 5-HIAA/5-HT turnover ratios in DLB + D compared to AD + D subjects. Additionally, a 4- and 7-fold increase of DOPAC/DA and HVA/DA turnover ratios, and, a 10-fold decrease of thalamic DA levels in DLB + D compared to AD + D patients and control subjects was noticed. Regarding psychosis, hippocampal DA levels in the overall DLB group significantly correlated with Behave-AD AB scores. In the total AD group, DA levels and HVA/DA ratios in the amygdala significantly correlated with Behave-AD AB scores instead. CONCLUSIONS:Monoaminergic neurotransmitter alterations contribute differently to the pathophysiology of depression and psychosis in DLB as opposed to AD, with a severely decreased serotonergic neurotransmission as the main monoaminergic etiology of depression in DLB. Similarly, psychosis in DLB might, in part, be etiologically explained by dopaminergic alterations in the hippocampus, whereas in AD, the amygdala might be involved.

journal_name

Alzheimers Res Ther

authors

Vermeiren Y,Van Dam D,Aerts T,Engelborghs S,Martin JJ,De Deyn PP

doi

10.1186/s13195-014-0090-1

subject

Has Abstract

pub_date

2015-02-11 00:00:00

pages

7

issue

1

issn

1758-9193

pii

90

journal_volume

7

pub_type

杂志文章
  • Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals.

    abstract:BACKGROUND:Amyloid pathology, which is one of the characteristics of Alzheimer's disease (AD), results from altered metabolism of the beta-amyloid (Aβ) peptide in terms of synthesis, clearance, or aggregation. A decrease in cerebrospinal fluid (CSF) level Aβ1-42 is evident in AD, and the CSF ratio Aβ42/Aβ40 has recentl...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00696-1

    authors: Lehmann S,Dumurgier J,Ayrignac X,Marelli C,Alcolea D,Ormaechea JF,Thouvenot E,Delaby C,Hirtz C,Vialaret J,Ginestet N,Bouaziz-Amar E,Laplanche JL,Labauge P,Paquet C,Lleo A,Gabelle A,Alzheimer’s Disease Neuroimaging Initi

    更新日期:2020-10-02 00:00:00

  • Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial.

    abstract:INTRODUCTION:The long-term efficacy and safety of donepezil 10 mg in patients with dementia with Lewy bodies (DLB) were investigated in a 52-week Phase 3 trial. METHODS:This 52-week study consisted of 16-week randomized placebo-controlled (RCT) and 36-week open-label extension phases. Of 142 DLB patients enrolled in t...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-014-0081-2

    authors: Mori E,Ikeda M,Nagai R,Matsuo K,Nakagawa M,Kosaka K

    更新日期:2015-02-03 00:00:00

  • Subcortical hyperintensity volumetrics in Alzheimer's disease and normal elderly in the Sunnybrook Dementia Study: correlations with atrophy, executive function, mental processing speed, and verbal memory.

    abstract:INTRODUCTION:Subcortical hyperintensities (SHs) are radiological entities commonly observed on magnetic resonance imaging (MRI) of patients with Alzheimer's disease (AD) and normal elderly controls. Although the presence of SH is believed to indicate some form of subcortical vasculopathy, pathological heterogeneity, me...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt279

    authors: Ramirez J,McNeely AA,Scott CJ,Stuss DT,Black SE

    更新日期:2014-08-11 00:00:00

  • Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.

    abstract:BACKGROUND:Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by neuropathologic changes involving beta-amyloid (Aβ), tau, neuronal loss, and other associated biological events. While levels of cerebrospinal fluid (CSF) Aβ and tau peptides have enhanced the antemortem detection of AD-specifi...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s13195-018-0426-3

    authors: Gangishetti U,Christina Howell J,Perrin RJ,Louneva N,Watts KD,Kollhoff A,Grossman M,Wolk DA,Shaw LM,Morris JC,Trojanowski JQ,Fagan AM,Arnold SE,Hu WT

    更新日期:2018-09-25 00:00:00

  • Subjective cognitive decline and subsequent dementia: a nationwide cohort study of 579,710 people aged 66 years in South Korea.

    abstract:BACKGROUND:Subjective cognitive decline (SCD) is a potential risk factor for dementia. We aimed to investigate the association between SCD and subsequent dementia in a nationwide population-based cohort in South Korea. METHODS:This cohort included 579,710 66-year-old adults who were followed for a total of 3,870,293 p...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00618-1

    authors: Lee YC,Kang JM,Lee H,Kim K,Kim S,Yu TY,Lee EM,Kim CT,Kim DK,Lewis M,Won HH,Jessen F,Myung W

    更新日期:2020-05-06 00:00:00

  • Diffusion kurtosis imaging allows the early detection and longitudinal follow-up of amyloid-β-induced pathology.

    abstract:BACKGROUND:Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia in the elderly population. In this study, we used the APP/PS1 transgenic mouse model to explore the feasibility of using diffusion kurtosis imaging (DKI) as a tool for the early detection of microstruct...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0329-8

    authors: Praet J,Manyakov NV,Muchene L,Mai Z,Terzopoulos V,de Backer S,Torremans A,Guns PJ,Van De Casteele T,Bottelbergs A,Van Broeck B,Sijbers J,Smeets D,Shkedy Z,Bijnens L,Pemberton DJ,Schmidt ME,Van der Linden A,Verhoye M

    更新日期:2018-01-09 00:00:00

  • Systemic and central nervous system metabolic alterations in Alzheimer's disease.

    abstract:BACKGROUND:Metabolic alterations, related to cerebral glucose metabolism, brain insulin resistance, and age-induced mitochondrial dysfunction, play an important role in Alzheimer's disease (AD) on both the systemic and central nervous system level. To study the extent and significance of these alterations in AD, quanti...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0551-7

    authors: van der Velpen V,Teav T,Gallart-Ayala H,Mehl F,Konz I,Clark C,Oikonomidi A,Peyratout G,Henry H,Delorenzi M,Ivanisevic J,Popp J

    更新日期:2019-11-28 00:00:00

  • In vivo quantification of neurofibrillary tangles with [18F]MK-6240.

    abstract:BACKGROUND:Imaging agents capable of quantifying the brain's tau aggregates will allow a more precise staging of Alzheimer's disease (AD). The aim of the present study was to examine the in vitro properties as well as the in vivo kinetics, using gold standard methods, of the novel positron emission tomography (PET) tau...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0402-y

    authors: Pascoal TA,Shin M,Kang MS,Chamoun M,Chartrand D,Mathotaarachchi S,Bennacef I,Therriault J,Ng KP,Hopewell R,Bouhachi R,Hsiao HH,Benedet AL,Soucy JP,Massarweh G,Gauthier S,Rosa-Neto P

    更新日期:2018-07-31 00:00:00

  • An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.

    abstract:INTRODUCTION:Amyloid-β (Aβ) has been investigated as a diagnostic biomarker and therapeutic drug target. Recent studies found that cerebrospinal fluid (CSF) Aβ fluctuates over time, including as a diurnal pattern, and increases in absolute concentration with serial collection. It is currently unknown what effect differ...

    journal_title:Alzheimer's research & therapy

    pub_type: 临床试验,杂志文章

    doi:10.1186/s13195-015-0136-z

    authors: Lucey BP,Gonzales C,Das U,Li J,Siemers ER,Slemmon JR,Bateman RJ,Huang Y,Fox GB,Claassen JA,Slats D,Verbeek MM,Tong G,Soares H,Savage MJ,Kennedy M,Forman M,Sjögren M,Margolin R,Chen X,Farlow MR,Dean RA,Waring J

    更新日期:2015-07-29 00:00:00

  • LW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAβPPswe/PS1ΔE9 transgenic mice.

    abstract:BACKGROUND:Accumulating evidence implicates the neuroendocrine immunomodulation (NIM) network in the physiopathological mechanism of Alzheimer's disease (AD). Notably, we previously revealed that the NIM network is dysregulated in the PrP-hAβPPswe/PS1ΔE9 (APP/PS1) transgenic mouse model of AD. METHODS:After treatment ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-016-0226-6

    authors: Wang JH,Lei X,Cheng XR,Zhang XR,Liu G,Cheng JP,Xu YR,Zeng J,Zhou WX,Zhang YX

    更新日期:2016-12-13 00:00:00

  • Biomarkers in biological fluids for dementia with Lewy bodies.

    abstract::Dementia with Lewy bodies (DLB) has become the second most common neurodegenerative dementia due to demographic ageing. Differential diagnosis is still troublesome especially in early stages of the disease, since there is a great clinical and neuropathological overlap primarily with Alzheimer's disease and Parkinson's...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-014-0072-3

    authors: Schade S,Mollenhauer B

    更新日期:2014-10-16 00:00:00

  • Older patients are still under-represented in clinical trials of Alzheimer's disease.

    abstract:BACKGROUND:The age gap between participants in trials and patients who could benefit from the drugs studied has been widely documented across different clinical areas. Patients with dementia included in clinical research are systematically younger than those in the general population. We examined the age gap between pa...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-016-0201-2

    authors: Banzi R,Camaioni P,Tettamanti M,Bertele' V,Lucca U

    更新日期:2016-08-12 00:00:00

  • Compression or expansion of dementia in Germany? An observational study of short-term trends in incidence and death rates of dementia between 2006/07 and 2009/10 based on German health insurance data.

    abstract:INTRODUCTION:There have been recent reports about a decline in dementia incidence, but only little is known about trends in the mortality of patients with dementia. Only the simultaneous analysis of both trends can inform whether the reported decline in dementia has led to a compression of dementia into higher ages. M...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0146-x

    authors: Doblhammer G,Fink A,Zylla S,Willekens F

    更新日期:2015-11-05 00:00:00

  • Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph.

    abstract:BACKGROUND:Recent Genome Wide Association Studies (GWAS) have identified novel rare coding variants in immune genes associated with late onset Alzheimer's disease (LOAD). Amongst these, a polymorphism in phospholipase C-gamma 2 (PLCG2) P522R has been reported to be protective against LOAD. PLC enzymes are key elements ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0469-0

    authors: Magno L,Lessard CB,Martins M,Lang V,Cruz P,Asi Y,Katan M,Bilsland J,Lashley T,Chakrabarty P,Golde TE,Whiting PJ

    更新日期:2019-02-02 00:00:00

  • The Third French Alzheimer Plan: analysis of the influence of a national public health initiative on scientific research productivity and impact.

    abstract:INTRODUCTION:The Third National Alzheimer Plan (2008-2012) was a major public health initiative in France that included €200 million of funding for research in Alzheimer disease and related disorders (AD). The aim of this study was to document trends in French academic output in AD following the implementation of the p...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0144-z

    authors: Haeffner-Cavaillon N,Devos P,Ledoux S,Ménard J

    更新日期:2015-09-26 00:00:00

  • Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment.

    abstract:BACKGROUND:In patients with amyloid-positive mild cognitive impairment (MCI), neurodegenerative biomarkers such as medial temporal lobe atrophy (MTA) are useful to predict disease progression to dementia. Although posterior atrophy (PA) is a well-known neurodegenerative biomarker of Alzheimer's disease, little is known...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-017-0326-y

    authors: Pyun JM,Park YH,Kim HR,Suh J,Kang MJ,Kim BJ,Youn YC,Jang JW,Kim S,Alzheimer’s Disease Neuroimaging Initiative.

    更新日期:2017-12-16 00:00:00

  • Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer's disease.

    abstract:INTRODUCTION:There has been a significant increase in the use of testosterone in aging men, but little investigation into its impact on men with Alzheimer's disease (AD). The findings of the few studies that have been done are inconsistent. In the present study, we investigated the relationship between total testostero...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-015-0107-4

    authors: Hall JR,Wiechmann AR,Cunningham RL,Johnson LA,Edwards M,Barber RC,Singh M,Winter S,O'Bryant SE,Texas Alzheimer’s Research and Care Consortium.

    更新日期:2015-05-01 00:00:00

  • Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.

    abstract:BACKGROUND:Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer's disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomar...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-019-0545-5

    authors: Ashton NJ,Suárez-Calvet M,Heslegrave A,Hye A,Razquin C,Pastor P,Sanchez-Valle R,Molinuevo JL,Visser PJ,Blennow K,Hodges AK,Zetterberg H

    更新日期:2019-11-28 00:00:00

  • Amyloid β-protein oligomers and Alzheimer's disease.

    abstract::The oligomer cascade hypothesis, which states that oligomers are the initiating pathologic agents in Alzheimer's disease, has all but supplanted the amyloid cascade hypothesis, which suggested that fibers were the key etiologic agents in Alzheimer's disease. We review here the results of in vivo, in vitro and in silic...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/alzrt226

    authors: Hayden EY,Teplow DB

    更新日期:2013-11-29 00:00:00

  • Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative.

    abstract:BACKGROUND:Optical coherence tomography (OCT) of the retina is a fast and easily accessible tool for the quantification of retinal structural measurements. Multiple studies show that patients with Alzheimer's disease (AD) exhibit thinning in several retinal layers compared to age-matched controls. Subjective cognitive ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00602-9

    authors: Marquié M,Valero S,Castilla-Marti M,Martínez J,Rodríguez-Gómez O,Sanabria Á,Tartari JP,Monté-Rubio GC,Sotolongo-Grau O,Alegret M,Pérez-Cordón A,Roberto N,de Rojas I,Moreno-Grau S,Montrreal L,Hernández I,Rosende-Roca M,M

    更新日期:2020-03-31 00:00:00

  • Should interventions to treat or prevent Alzheimer's disease be tested in a population or as targeted treatment of highly selected study participants?

    abstract::Symptomatic treatments for Alzheimer's disease should retain a place in the advanced stages of disease since their actions on these symptoms, even if not modifying the course of disease, are critical for improving patients' comfort and reducing the burden felt by caregivers, especially those facing behavioral disorder...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt228

    authors: Ousset PJ,Delrieu J,Vellas B

    更新日期:2013-12-11 00:00:00

  • Brain volumes and cortical thickness on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER).

    abstract:BACKGROUND:The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) was a multicenter randomized controlled trial that reported beneficial effects on cognition for a 2-year multimodal intervention (diet, exercise, cognitive training, vascular risk monitoring) versus control (gene...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1186/s13195-019-0506-z

    authors: Stephen R,Liu Y,Ngandu T,Antikainen R,Hulkkonen J,Koikkalainen J,Kemppainen N,Lötjönen J,Levälahti E,Parkkola R,Pippola P,Rinne J,Strandberg T,Tuomilehto J,Vanninen R,Kivipelto M,Soininen H,Solomon A,FINGER study grou

    更新日期:2019-06-04 00:00:00

  • Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment: a critical review.

    abstract:BACKGROUND:A growing number of pharmacological and nonpharmacological trials have been performed to test the efficacy of approved or experimental treatments in Alzheimer disease (AD) and mild cognitive impairment (MCI). In this context, functional magnetic resonance imaging (fMRI) may be a good candidate to detect brai...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/s13195-018-0347-1

    authors: Canu E,Sarasso E,Filippi M,Agosta F

    更新日期:2018-02-20 00:00:00

  • Kidney function and dementia risk in community-dwelling older adults: the Shanghai Aging Study.

    abstract:BACKGROUND:Association between kidney dysfunction and dementia has been studied in western cohorts, but with inconsistent conclusions which may be due to the different measurements of kidney function. We aim to verify the hypothesis that lower levels of kidney function would be associated with increased risk of inciden...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-020-00729-9

    authors: Wang M,Ding D,Zhao Q,Wu W,Xiao Z,Liang X,Luo J,Chen J

    更新日期:2021-01-11 00:00:00

  • Early brain connectivity alterations and cognitive impairment in a rat model of Alzheimer's disease.

    abstract:BACKGROUND:Animal models of Alzheimer's disease (AD) are essential to understanding the disease progression and to development of early biomarkers. Because AD has been described as a disconnection syndrome, magnetic resonance imaging (MRI)-based connectomics provides a highly translational approach to characterizing th...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-018-0346-2

    authors: Muñoz-Moreno E,Tudela R,López-Gil X,Soria G

    更新日期:2018-02-07 00:00:00

  • Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.

    abstract:BACKGROUND:Development of new treatments for Alzheimer's disease (AD) has broadened into early interventions in individuals with modest cognitive impairment and a slow decline. The 11-item version of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) was originally developed to measure cognition in ...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/s13195-016-0170-5

    authors: Podhorna J,Krahnke T,Shear M,Harrison JE,Alzheimer’s Disease Neuroimaging Initiative.

    更新日期:2016-02-12 00:00:00

  • Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease.

    abstract:INTRODUCTION:Peripheral biomarkers to diagnose Alzheimer's disease (AD) have not been established. Given parallels between neuron and platelet biology, we hypothesized platelet membrane-associated protein changes may differentiate patients clinically defined with probable AD from noncognitive impaired controls. METHOD...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章

    doi:10.1186/alzrt186

    authors: Donovan LE,Dammer EB,Duong DM,Hanfelt JJ,Levey AI,Seyfried NT,Lah JJ

    更新日期:2013-06-13 00:00:00

  • Potential sources of interference on Abeta immunoassays in biological samples.

    abstract::Therapeutic products that depend on the use of an in vitro diagnostic biomarker test to confirm their effectiveness are increasingly being developed. Use of biomarkers is particularly meaningful in the context of selecting the patient population where the therapeutic treatment is believed to be efficacious (patient en...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,评审

    doi:10.1186/alzrt142

    authors: Vanderstichele H,Stoops E,Vanmechelen E,Jeromin A

    更新日期:2012-10-17 00:00:00

  • Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.

    abstract:BACKGROUND:Several monoclonal antibodies for the treatment of Alzheimer's disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils. METHODS:Here we describe the first clinical study with BAN2401. Safety and tolerability were...

    journal_title:Alzheimer's research & therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1186/s13195-016-0181-2

    authors: Logovinsky V,Satlin A,Lai R,Swanson C,Kaplow J,Osswald G,Basun H,Lannfelt L

    更新日期:2016-04-06 00:00:00

  • Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.

    abstract:BACKGROUND:Whether age at onset influences Alzheimer's disease (AD) progression and the effectiveness of cholinesterase inhibitor (ChEI) therapy is not clear. We aimed to compare longitudinal cognitive and global outcomes in ChEI-treated patients with early-onset Alzheimer's disease (EOAD) versus late-onset Alzheimer's...

    journal_title:Alzheimer's research & therapy

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s13195-017-0294-2

    authors: Wattmo C,Wallin ÅK

    更新日期:2017-08-31 00:00:00